OrigiMed has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. (Janssen).

Leveraging the power of real-world evidence, both parties will jointly explore to optimize clinical trials and patient enrollment, develop clinical innovative solutions, boost the development and commercialization processes of companion diagnostic products and anti-tumor drugs by virtue of their strong scientific research capabilities and extensive medical resources, thereby providing comprehensive health management solutions for patients.

As a leading anti-tumor precision medicine company in China, OrigiMed will establish a comprehensive digital service platform and optimize the marketing strategy for new anti-tumor drugs and companion diagnostic products based on its excellent next-generation sequencing (NGS) technology and cutting-edge technologies such as gene database, patient follow-up database, and real-world study and evidence.